Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Operating Leases (2020 - 2023)

Insight Molecular Diagnostics' Operating Leases history spans 4 years, with the latest figure at $2.1 million for Q4 2023.

  • For Q4 2023, Operating Leases fell 38.68% year-over-year to $2.1 million; the TTM value through Dec 2023 reached $2.1 million, down 38.68%, while the annual FY2023 figure was $2.1 million, 38.68% down from the prior year.
  • Operating Leases for Q4 2023 was $2.1 million at Insight Molecular Diagnostics, down from $2.6 million in the prior quarter.
  • Across five years, Operating Leases topped out at $4.3 million in Q4 2020 and bottomed at $2.1 million in Q4 2023.
  • The 4-year median for Operating Leases is $3.5 million (2021), against an average of $3.4 million.
  • The largest annual shift saw Operating Leases fell 3.3% in 2022 before it tumbled 38.68% in 2023.
  • A 4-year view of Operating Leases shows it stood at $4.3 million in 2020, then decreased by 17.79% to $3.5 million in 2021, then dropped by 3.3% to $3.4 million in 2022, then crashed by 38.68% to $2.1 million in 2023.
  • Per Business Quant, the three most recent readings for IMDX's Operating Leases are $2.1 million (Q4 2023), $2.6 million (Q1 2023), and $3.4 million (Q4 2022).